Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2025-12-25 @ 1:31 AM
NCT ID:
NCT00915694
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed WHO grade IV supratentorial astrocytoma (glioblastoma multiforme)
* Newly diagnosed disease
* Has undergone maximal surgical resection
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Serum creatinine \< 1.5 times upper limit of normal (ULN)
* AST or ALT \< 2 times ULN
* Serum bilirubin \< 1.5 mg/dL
* No known HIV infection
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior cranial radiotherapy
* More than 30 days since prior investigational agents
* No other concurrent investigational agents
* No concurrent use of any of the following drugs:
* Antiarrhythmics (i.e., amiodarone or quinidine)
* Antimycobacterials (i.e., rifampin)
* Ergot derivatives (i.e., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
* Herbal products (i.e., St. John's wort)
* HMG-CoA reductase inhibitors (i.e., lovastatin or simvastatin)
* Neuroleptics (i.e., pimozide)
* Sedatives and/or hypnotics (i.e., midazolam or triazolam)
* Concurrent corticosteroids allowed provided dose has been stable or decreasing for ≥ 14 days prior to study entry
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT00915694
Study Brief:
Protocol Section:
NCT00915694